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Campus, Aurora, ColoradoABSTRACT Deficiency of the vital muscle protein dystrophin triggers Duchenne/Becker muscular dystrophy, but the structure-
function relationship of dystrophin is poorly understood. To date, molecular structures of three dystrophin domains have been
determined, of which the N-terminal actin-binding domain (N-ABD or ABD1) is of particular interest. This domain is composed of
two calponin-homology (CH) domains, which form an important class of ABDs in muscle proteins. A previously determined x-ray
structure indicates that the dystrophin N-ABD is a domain-swapped dimer, with each monomer adopting an extended, open
conformation in which the two CH domains do not interact. This structure is controversial because it contradicts functional
studies and known structures of similar ABDs from other muscle proteins. Here, we investigated the solution conformation of
the dystrophin N-ABD using a very simple and elegant technique of pyrene excimer fluorescence. Using the wild-type protein,
which contains two cysteines, and the corresponding single-cysteine mutants, we show that the protein is a monomer in solution
and is in a closed conformation in which the two CH domains seem to interact, as observed from the excimer fluorescence of
pyrene-labeled wild-type protein. Excimer fluorescence was also observed in its actin-bound form, indicating that the dystrophin
N-ABD binds to F-actin in a closed conformation. Comparison of the dystrophin N-ABD conformation with other ABDs indicates
that the tandemCH domains in general may be monomeric in solution and predominantly occur in closed conformation, whereas
their actin-bound conformations may differ.INTRODUCTIONMuscular dystrophy (MD) is the most common genetic
lethal disorder in children (1). Mutations in the gene encod-
ing the vital muscle protein dystrophin trigger the two most
common forms of MD: Duchenne and Becker. Dystrophin
stabilizes the muscle cell membrane against the mechanical
forces associated with muscle contraction and stretch by
connecting actin filaments to the sarcolemmal glycoprotein
complex (2,3). Despite its well-established role in MD, the
relationship between the structure and function of dystro-
phin is poorly understood.
Dystrophin is a long, rod-shaped molecule containing
3685 amino acids (4). Because of its large size, it is cur-
rently not possible to determine the molecular structure of
the complete protein. Therefore, research focus has shifted
toward determining the structures of individual domains.
So far, the molecular structures have been determined
for <14% of the full-length protein (3), which stresses
the need for more structural studies on dystrophin to under-
stand how its structure controls function. Of the three
dystrophin domains whose structures are known (5,6), the
N-terminal actin-binding domain (N-ABD or ABD1) is of
particular interest because of its role in the most important
function of dystrophin, i.e., actin binding. In addition, a
major fraction of disease-causing missense mutations occur
in this domain (7,8), and probing its structure-functionSubmitted May 30, 2012, and accepted for publication August 20, 2012.
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0006-3495/12/11/1970/9 $2.00relationship and the effect of mutations might help in
understanding the mechanisms by which the disease is trig-
gered. A previously determined x-ray crystal structure of
the dystrophin N-ABD indicates that it is an antiparallel
domain-swapped dimer (Fig. 1 a) (5), with each monomer
existing in an extended, open conformation. This dimeric
crystal structure is controversial. Biochemical (9–11) and
recent biophysical studies (7,12) indicate that the dystro-
phin N-ABD might be a monomer in solution. In addition,
similar ABDs from other muscle proteins, such as utrophin
(13,14), fimbrin (15), plectin (16), and a-actinin (17), are
monomers. Therefore, we must first resolve the controversy
regarding the solution structure of the dystrophin N-ABD,
before determining its structure-function relationship and
the effects of disease-causing mutations.
In addition, studying the structure-function relationship
of the dystrophin N-ABD might improve the efficacy
of mini-dystrophins. These proteins are currently under clin-
ical trials to treat the loss of functional dystrophin in MD
patients (18,19), but they tend to have decreased stability,
functionality, and in-vivo half-life (20–22) compared to
the full-length dystrophin. All these proteins contain the
N-ABD. Therefore, one method of stabilizing the mini-
dystrophins might be to increase the stability of the compo-
nent domains, for example, that of N-ABD. Understanding
the structural principles that govern N-ABD function
might lead to improving actin-binding efficiency of mini-
dystrophins.http://dx.doi.org/10.1016/j.bpj.2012.08.066
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a b FIGURE 1 (a) X-ray crystal structure of the
N-ABD of human dystrophin (1DXX.pdb) indicates
an antiparallel, domain-swapped dimer (5). The two
monomers, labeled A and B, are shown in gray and
red, respectively. In the dimer, the CH1 domain
from one monomer interacts with the CH2 domain
from the other monomer. Each monomer contains
two cysteines (Cys-10 and Cys-188), one in each
CH domain, at an intramolecular distance of 56 A˚.
(b) Structural alignment of x-ray crystal struc-
tures of tandem CH domains of dystrophin
(1DXX.pdb; gray), utrophin (1QAG.pdb; red), fim-
brin (1AOA.pdb; blue), a-actinin (1TJT.pdb; green),
and plectin (1MB8.pdb; yellow) using the MultiProt
program (47) (http://bioinfo3d.cs.tau.ac.il/MultiProt/).
Dystrophin and utrophin tandem CH domains
crystallize in an open conformation where the two
CH domains do not interact, whereas tandem CH
domains of fimbrin, a-actinin, and plectin crystallize
in a closed conformation with significant inter-
CH domain interactions. The N-terminal (CH1) and C-terminal (CH2) CH domains are labeled in the figure. Molecular structures were drawn using the
program Accelrys Discovery Studio Visualizer (http://accelrys.com/products/discovery-studio/visualization-download.php).
Solution Conformation of the Tandem CH Domain of Dystrophin 1971Determining the solution conformation of the dystrophin
N-ABD might provide new insights into the structural plas-
ticity of tandem calponin-homology (CH) domains, which
form an important class of ABDs in muscle proteins
(10,23). The dystrophin N-ABD contains two CH domains
in tandem (5). In its dimeric crystal structure (Fig. 1 a),
each monomer is in an open, extended conformation with
no significant interactions between the N-terminal (CH1)
and C-terminal (CH2) CH domains. However, this open
conformation of the dystrophin N-ABD contradicts the
structures of other tandem CH domains, for example, those
of fimbrin (15), plectin (16), and a-actinin (17), which crys-
tallize in a closed, compact conformation with significant
interactions between the individual CH domains (Fig. 1
b). The tandem CH domain from another homologous
protein, utrophin, crystallizes as an antiparallel dimer
similar to that of dystrophin with each monomer in an
open conformation (14) (Fig. 1 b), however, recent solution
studies show that it exists in both closed and open conforma-
tions (24,25). These recent studies (24,25) also indicate that
the solution conformation of tandem CH domains might
differ from their crystal structures, and stresses the need to
determine their solution structures. Similar to the conforma-
tional differences of tandem CH domains, their mode of
binding to F-actin and associated conformational changes
are also controversial. No high-resolution molecular struc-
tures are available for these proteins in their actin-bound
form, and the low-resolution cryo-electron microscopy
(cryo-EM) data have been used to deduce contradicting
conclusions (10,23,26). For example, cryo-EM data on the
actin-bound tandem CH domain of utrophin have led to
the conclusion that it is in a closed conformation (27),
whereas similar data have been used to conclude that it is
in an open conformation (28,29). Thus, a controversy has
arisen as to whether the tandem CH domains bind to F-actinin a closed or open conformation (26). The cryo-EM data on
the two tandem CH domains of fimbrin suggest that they
bind to F-actin in closed conformations (30,31). Cryo-EM
studies on a-actinin’s tandem CH domain indicate that it
binds to F-actin in an open conformation (32). In the case
of cryo-EM studies on actin-bound dystrophin N-ABD
(27), the extent of labeling was poor; however, the available
data suggest that it might bind to F-actin in a closed confor-
mation, although further definitive experiments are needed
to determine its actin-bound conformation. In light of these
controversies associated with the crystal structures and the
actin-bound conformations of tandem CH domains inter-
preted from cryo-EM studies, we were in search of a very
simple method that could help determine whether the
tandem CH domains exist in a closed or open conformation
in solution. We found our answer in the technique of pyrene
excimer fluorescence.
The main principle behind pyrene excimer fluorescence
is that when an excited pyrene molecule is close in three-
dimensional (3D) space to a neighboring, ground-state
pyrene, their aromatic rings stack against each other to
form a dimer (excited-state dimer or excimer). This results
in a new fluorescence emission band at ~470 nm (33–35),
which is quite distinct from the fluorescence of monomeric
pyrene that occur at ~375 nm. Pyrenes can be covalently
linked to cysteine residues in proteins using maleimide
chemistry (33). Considering the length of the linkers, if
the two labeled positions are within a distance of %23 A˚
in the 3D protein structure (33,34,36), excimer fluores-
cence can be expected. Unlike the commonly used fluo-
rescence resonance energy transfer techniques, pyrene
excimer fluorescence does not provide any information
about the exact distances, and in that sense, it provides
more of a yes/no answer where the observation of excimer
fluorescence indicates that the two labeled positions areBiophysical Journal 103(9) 1970–1978
1972 Singh and Mallelaclose in 3D space. This technique has been extensively
used to probe conformational transitions of proteins
(33,36–39), and also the dynamics of actin and actin-
binding proteins (11,34,40–42). The wild-type (WT) dys-
trophin N-ABD contains cysteines at positions 10 in the
CH1 domain and 188 in the CH2 domain, which are not
involved in a disulfide bond (Fig. 1 a). We therefore de-
signed two single-cysteine mutants, namely C10S and
C188S, by mutating one of the cysteines to serine. We
labeled the WT and the mutants using pyrene maleimide.
Using the excimer fluorescence of these proteins, we ad-
dressed three important issues: 1), whether the dystrophin
N-ABD is a dimer in solution; 2), whether it is in an
open conformation in solution, similar to that in the crystal
structure (Fig. 1 a); and 3), whether it is in a closed confor-
mation in its actin-bound form, as predicted by the low-
resolution cryo-EM studies (27).MATERIALS AND METHODS
Cloning, expression, and purification
The cDNA coding for dystrophin N-ABD (residues 1–246; a kind gift from
Steve Winder, University of Sheffield, UK) was amplified using poly-
merase chain reaction, subcloned into pET28a expression vector using
NdeI and HindIII restriction sites, and transformed into DH5a by heat-
shock method. The plasmid was amplified using the Qiagen miniprep kit
(Valencia, CA), and single cysteine mutants (C10S, C188S) were gener-
ated using the Qiaquick mutagenesis protocol. Amplified DNA sequences
of dystrophin N-ABD and its mutants were confirmed by DNA
sequencing. All three plasmids were transformed into BL21-DE3 by the
heat-shock method, and glycerol stocks were made for further expression
and purification. A 2-L culture of transformed bacteria in LB broth was
induced with 0.5 mM IPTG for 3 h at 37C, and the cells were harvested
as a pellet. For the purification of dystrophin N-ABD, the cell pellet was
suspended in a buffer containing 50 mM Tris, 200 mM NaCl, pH 7, 1 mM
PMSF, and lysed by sonication (15 cycles at 20-watt power and 45%
amplitude, each of 20 s duration with 20 s gaps between cycles, and
with samples kept on ice). The lysed cell suspension was centrifuged at
30,000  g using a SS-34 rotor (Sorvall, Newtown, CT) and Oak Ridge
centrifuge tubes (Nalgene, Penfield, NY). The supernatant was centrifuged
again and the soluble protein from clear supernatant was purified using
Ni-Sepharose Fast Flow (GE Healthcare, Buckinghamshire, UK) metal
affinity chromatography. The purity of the protein was evaluated using
SDS-PAGE (Fig. 2 a). Pure elutes were pooled and dialyzed against phos-
phate buffered saline (PBS) buffer (0.1 M NaH2PO4, 0.15 M NaCl, pH 7).
Single cysteine mutants were purified using the same protocol as described
above for the WT protein.M WT C1
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Biophysical Journal 103(9) 1970–1978Circular dichroism and fluorescence
measurements
Circular dichroism (CD) spectra of pure proteins (5 mM) were recorded in
PBS buffer using a Chirascan Plus spectrometer (Applied Photophysics,
Leatherhead, UK). Thermal melts were recorded using a continuous temper-
ature ramp. Urea (Nacalai Tesque, Kyoto, Japan; Code No. 35940-81) was
used to measure the stability of dystrophin N-ABD in PBS buffer. For this
experiment, buffer samples with varying urea concentration were initially
prepared and the protein was added from a stock solution. The samples
were equilibrated for 1 h before recording the CD or fluorescence signals.
Fluorescence measurements were made using a PTI Fluorometer (South
Brunswick, NJ). The data were normalized from 0 to 1 before plotting.Pyrene labeling
WT and mutant N-ABDs were labeled with pyrene using the reagent
N-(1-pyrene)maleimide (Molecular Probes, Eugene, OR). A stock of
5 mM N-(1-pyrene)maleimide was made in acetonitrile. Single cysteine
mutants (20 mM)were reacted with 20 mMN-(1-pyrene)maleimide, whereas
theWT (20 mM)was reacted with 40 mM N-(1-pyrene)maleimide because it
contains two cysteine reactive groups. The reaction was carried out at room
temperature overnight (12 h). Proteins were exchanged into PBS using
PD-10 prepacked columns with Sephadex G25 (GE Lifesciences).
Percentage labeling was estimated using a PM-Cysteine molar extinction
coefficient of 37,500 M1cm1 at 343 nm (Molecular Probes Handbook)
and micro-BCA protein estimation kit (Pierce, Franklin, MA).Actin binding
Rabbit skeletal muscle actin (Cytoskeleton, Denver, CO) was polymerized
into F-actin by incubating in polymerization buffer (10, 0.5 M KCl,
20 mM MgCl2, 10 mM ATP) for 1 h at room temperature. Fluorescence
spectra of pyrene-labeled proteins (10 mM) were recorded in the absence
and presence of F-actin (10 mM) on a PTI fluorometer with excitation at
345 nm. Spectra were normalized to the intensity of the pyrene monomer
fluorescence peak at 375 nm.RESULTS AND DISCUSSION
Cysteine mutations did not affect the structure
and stability of dystrophin N-ABD
When expressed in Escherichia coli and purified using
affinity chromatography, we obtained high yields of highly
pure WT dystrophin N-ABD and its single-cysteine mutants
(Fig. 2 a). We first confirmed that the mutations did not
significantly alter the structure or stability of the N-ABD.
Mutants had CD spectra similar to that of the WT protein,mperature (K)
320 340
FIGURE 2 (a) SDS-PAGE of the purified WT
dystrophin N-ABD and its two single-cysteine
mutants C10S and C188S. Lane M represents the
molecular mass markers (bottom to top: 17, 26, 34,
43, 56, 72, 95, 130, and 170 kDa, respectively).
(b) CD spectrum of the WT and two mutants
(5 mM). Note that all three spectra essentially overlap.
(c) Thermal melts of the WTand two mutants (5 mM).
As shown, cysteine mutations did not affect the
protein structure (panel b) or stability (panel c).
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Solution Conformation of the Tandem CH Domain of Dystrophin 1973with minima at 208 and 222 nm characteristic of a-helical
secondary structure (Fig. 2 b). When the proteins were sub-
jected to thermal denaturation, the mutants unfolded with
a midpoint temperature (Tm ¼ 331.3 5 0.9 K) similar to
that of the WT protein (Fig. 2 c). Although these tempera-
ture melts are not reversible, they do indicate that the protein
stability does not change upon mutations.b
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FIGURE 3 Dystrophin N-ABD is a monomer in solution. (a) Pyrene
fluorescence of single-cysteine mutants (C188S (C10-Py) and C10S
(C188-Py); 10 mM), and when mixed at equimolar ratio (C10-Py þ
C188-Py; 10 mM total protein concentration). The absence of excimer fluo-
rescence indicates the absence of dimers or higher oligomers in solution. (b)
Thermodynamic stability of dystrophin N-ABD measured at 1 and 10 mM.
Urea was used to unfold the protein, and the CD at 222 nm was used to
monitor unfolding of the a-helical secondary structure of the protein. The
stability is independent of the protein concentration confirming the absence
of stable dimers at or below 10 mM protein concentration. (c) Native PAGE
of dystrophin N-ABD with 5 and 10 mg loading protein amounts. A similar
result was observed even when the gel was overloaded with 30 mg of
protein (7).Dystrophin N-ABD is a monomer in solution
We monitored excimer fluorescence of the pyrene-labeled
C188S mutant, which has a single cysteine residue at posi-
tion 10 in the CH1 domain (Fig. 1 a). We expected to
observe excimer fluorescence if the protein formed a parallel
dimer in which the CH1 domain of one monomer is close to
that of the adjacent monomer, allowing the pyrenes from the
two monomers to stack against one another. Alternatively,
nonspecific labeling of residues other than C10 within the
CH1 domain during the labeling reaction might result in
stacking of the two pyrene molecules from the same mono-
mer resulting in excimer fluorescence. Under our experi-
mental conditions, the fraction of the labeled protein
was ~0.55 5 0.05, and we did not observe any excimer
fluorescence (C10-Py in Fig. 3 a), indicating the absence
of parallel dimers or nonspecific labeling. We similarly
investigated the presence of excimer fluorescence in C10S
single-cysteine mutant, which has a single cysteine residue
at position 188 in the CH2 domain (Fig. 1 a). Under the
labeling conditions we used, the fraction of labeled protein
was ~0.43 5 0.05, and we did not observe any excimer
fluorescence (C188-Py in Fig. 3 a), indicating the absence
of parallel dimers or nonspecific labeling within the CH2
domain.
Next, we investigated excimer fluorescence in an equi-
molar (1:1) mixture of the pyrene-labeled single-cysteine
mutants C188S and C10S (C10-Py þ C188-Py in
Fig. 3 a). If the protein formed an antiparallel dimer as
observed in the x-ray crystal structure (Fig. 1 a) in which
C10 in one monomer is close to the C188 residue in the
other monomer, or if there had been nonspecific labeling
anywhere in the two CH domains, excimer fluorescence
might be expected. However, we observed no excimer fluo-
rescence (Fig. 3 a), indicating the absence of antiparallel
dimers or nonspecific labeling.
The dimer seen in x-ray crystal studies (Fig. 1 a) has been
proposed to form with a dimerization constant, Kd of 4 mM
(5). To exclude such possibility, we monitored the melting
of the protein secondary structure upon the addition of
urea using the CD signal at 222 nm at two different protein
concentrations 1 and 10 mM (Fig. 3 b). If there is a dimer
formation, the relative dimer concentration would be higher
at 10 mM compared to 1 mM; therefore, an increase in
protein stability would be expected at higher protein
concentration. The protein melting curves revealed an over-
lapping sigmoidal transition at the two concentrations(Fig. 3 b), indicating that the protein stability is independent
of the protein concentration, suggesting the absence of
dimers under our experimental conditions.Biophysical Journal 103(9) 1970–1978
1974 Singh and MallelaResults from our earlier NMR relaxation experiments
also support the previous conclusion that dystrophin’s
tandem CH domain is a monomer in solution (7). The rota-
tional correlation time (tc), calculated from the longitudinal
(T1) and transverse (T2) relaxation times, is close to that
expected for a monomer of the same size as that of dystro-
phin’s N-ABD. Furthermore, we ran native PAGE at
different protein concentrations (Fig. 3 c), to show that the
protein exists as a single species in solution. A single
band was observed on the native gel when the gel was
loaded with 5 and 10 mg of the protein. We also found
the same result with 30 mg of protein (7), indicating that
the protein sample contains a single species at all the
concentrations.
Taken together, results from all the previous experiments
(absence of excimer fluorescence (Fig. 3 a), denaturant melt
as a function of protein concentration (Fig. 3 b), NMR re-
laxation (7), and native gel (Fig. 3 c)) indicate that the dys-
trophin N-ABD is a monomer in solution, and if dimer
population is present, it should be minimal (at the most
5%) such that it does not significantly affect the measured
signals within the experimental errors.Dystrophin N-ABD is in a closed conformation
in solution
Now that we have shown that the N-ABD exists primarily as
a monomer in solution, we use the doubly labeled WT
protein to determine whether the protein exists in a closed
conformation similar to that observed in the x-ray structures
of ABDs of fimbrin (15), plectin (16), and a-actinin (17)
(Fig. 1 b), or if it exists in an open conformation observed in
its domain-swapped dimer crystal structure (5) (Fig. 1 a).
We monitored excimer fluorescence in the pyrene-labeled
WT protein, which has two cysteine residues, i.e., at posi-
tions 10 and 188. If the molecule exists in an open confor-
mation as indicated by the x-ray structure, the distance
between the two cysteines would be 56 A˚ (Fig. 1 a). In
such a conformation, no excimer fluorescence would be ex-
pected because the pyrene aromatic rings would be too far
apart to form an excited-state dimer. However, excimer fluo-
rescence might be observed if the protein is in a closed
conformation with significant interactions between the two
CH domains, allowing the pyrenes labeled at C10 and
C188 to stack against each other. Indeed, we observed an
additional fluorescence band at 467 nm (WT-Py in Fig. 4 a)
consistent with excimer formation, in addition to the pyrene
monomer fluorescence observed earlier with pyrene-labeled
single-cysteines mutants (C10-Py, C188-Py, and C10-Py þ
C188-Py in Fig. 4 a). This observation clearly indicates
that the protein exists in a closed conformation in solution,
contrary to the open conformation observed in the earlier
x-ray crystal studies (Fig. 1 a). Because the labeling reaction
was performed on the WT protein having two cysteines,
three species would be expected in solution: those havingBiophysical Journal 103(9) 1970–1978the pyrene label at C10 alone, C188 alone, and at both
C10 and C188. In this case, the fraction of the doubly
labeled protein would be the product of the probabilities
of labeling individual cysteines, C10 and C188, i.e.,
0.55  0.43 ¼ 0.24. Under the labeling conditions we
used, the fraction of the pyrene label per one protein mole-
cule was ~0.685 0.05. Because the pyrene monomer fluo-
rescence seen in Fig. 4 a originates from all three species
(doubly labeled, and two single-labeled proteins), whereas
excimer fluorescence originates only from the doubly
labeled protein, the excimer fluorescence intensity would
be expected to be higher than what was observed if the
sample contained 100% of the doubly labeled WT.
However, these experiments do not exclude the presence
of an open conformation that might not contribute to the
excimer fluorescence signal. The denaturant melting ex-
periments described below and in Fig. 4 b indicate that
the population of such an open conformation, if it exists,
would be minimal.
To exclude the possibility that the covalent labeling with
pyrene is changing the structure or dynamics of the protein,
we measured protein stability using urea as the denaturant
and pyrene excimer fluorescence as the signal, and we
made a comparison with the stability measured from the
melting of the secondary structure (CD at 222 nm) and
the tertiary structure (fluorescence of aromatic amino acids
with lex ¼ 280 nm) of the unlabeled protein (Fig. 4 b). All
three probes exhibited an overlapping sigmoidal, coopera-
tive melting transition with the same DG value (10.8 5
0.8 kcal/mol), indicating that the covalent labeling did not
alter the protein conformation. The denaturant melt moni-
tored by pyrene fluorescence has a native baseline with
a higher slope compared to that of CD and fluorescence,
which was expected because of the strong solvent depen-
dence of pyrene fluorescence demonstrated earlier (43).
However, the observation of a DG similar to that of fluores-
cence and CD indicates that the solution conformation de-
tected by pyrene excimer fluorescence represents the
average conformation of the entire protein ensemble. This
implies that if any open conformation exists in solution
that does not contribute to the excimer fluorescence signal,
it should be minimal; otherwise, the DG of the closed
conformation measured by pyrene excimer would differ
from the DG of the protein ensemble measured by CD and
fluorescence. In addition, labeled WT protein having the
same conformational stability as that of the unlabeled
monomeric protein excludes two other possibilities: 1),
covalent labeling of the WT protein with pyrenes is forcing
the protein to adopt a new conformation, and 2), covalent
labeling with pyrenes might favor dimer formation in the
doubly labeled WT protein.
Our previously published results (7) also support the
above conclusion that the dystrophin N-ABD is in a closed
conformation solution. The rotational correlation time (tc)
calculated from NMR relaxation experiments was 18 ns,
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FIGURE 4 Dystrophin N-ABD is in a closed conformation in solution.
(a) Pyrene fluorescence of the WT protein (WT-Py; 10 mM) in comparison
with that of the single-cysteine mutants, C188S (C10-Py; 10 mM), C10S
(C188-Py; 10 mM), and 1:1 C188S þ C10S (C10-Py þ C188-Py; 10 mM
total protein concentration). The arrow denotes the excimer fluorescence
of the WT protein, indicating that the protein is in a closed conformation
with two cysteines close in space. (b) Urea melting of pyrene excimer fluo-
rescence, in comparison with that measured by CD at 222 nm and aromatic
fluorescence (lex ¼ 280 nm) of the unlabeled protein. The protein con-
centration used in these experiments was 5 mM. All three signals measured
the same protein stability (DG ¼ 10.8 5 0.8 kcal/mol, m ¼ 1.9 5
0.1 kcal/mol/M [urea]) when fit to a 2-state Santoro-Bolen equation
(48,49), indicating that the pyrene labeling did not affect the protein struc-
ture. (c) Excitation spectra at different emission wavelengths. The spectrum
corresponding to the excimer fluorescence (lem ¼ 460 nm) is much broader
Solution Conformation of the Tandem CH Domain of Dystrophin 1975close to 16 ns if dystrophin N-ABD is a perfectly spherical
protein (7). Further evidence for the closed conformation of
the dystrophin N-ABD was obtained from the excitation
spectra of the pyrene monomer and excimer fluorescence.
If the dystrophin N-ABD is in a closed conformation, it is
quite likely that the pyrene dimers might be present in the
ground state. In such a case, the excitation spectrum corre-
sponding to the excimer fluorescence would be much
broader (33,34), because the excimer fluorescence origi-
nates from both ground-state pyrene monomer as well as
ground-state pyrene dimers. Our results (Fig. 4 c) confirmed
this scenario, i.e., the excimer fluorescence (lem ¼ 460 nm)
has much broader excitation spectrum than that of the
monomer fluorescence (lem ¼ 375 nm), supporting the
above conclusion that the dystrophin N-ABD is in a closed
conformation.Dystrophin N-ABD is in a closed conformation
upon binding to F-actin
Dystrophin N-ABD binds to F-actin with a Kd of 13 mM and
with 1:1 stoichiometry where one N-ABDmolecule binds to
one actin monomer (11). In F-actin, actin monomers are
separated by a translation of 27.5 A˚ and a rotation of 166
(44). Depending on the exact binding geometry, CH
domains from neighboring N-ABD molecules might come
close in space, as observed in an earlier cryo-EM study
(27). This would result in intermolecular pyrene excimer
formation, which does not provide information about the
conformation of individual protein molecules. To exclude
this probability, we performed the actin-binding experi-
ments under limited labeling conditions in which the WT
protein was labeled such that the fraction of the doubly
labeled protein was 10%, and correspondingly single-
cysteine mutants were labeled by 30%. We confirmed the
absence of intermolecular excimer fluorescence with the
pyrene-labeled single-cysteine mutants, C188S and C10S.
Upon adding F-actin, we did not observe an excimer fluores-
cence band (Fig. 5 a), indicating no intermolecular excimer
formation. Under identical conditions, the intensity of the
excimer fluorescence of the WT protein increased upon
binding to F-actin (Fig. 5 b). As stated previously, because
the WT contains two cysteines, the sample contained three
species, two single-labeled and one doubly labeled; there-
fore, the true increase in excimer fluorescence upon actin
binding would be higher than that observed in Fig. 5 b if
both the cysteines in the WT protein are labeled with pyr-
ene. Two possible scenarios could explain such an increase
in excimer fluorescence: the dystrophin N-ABD transitions
to a new conformation, bringing the two labeled cysteines
much closer in 3D space compared to its unbound form,than that of the monomer fluorescence (lem ¼ 375 nm), indicating that the
excimer fluorescence originates from both ground-state pyrene monomers
as well as dimers.
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FIGURE 5 Dystrophin N-ABD is in a closed
conformation when bound to F-actin. Panel (a)
shows the pyrene fluorescence of the two single-
cysteine mutants, C188S (C10-Py; 10 mM), C10S
(C188-Py; 10 mM), and 1:1 C10-Py þ C188-Py
(10 mM protein concentration), whereas panel
(b) shows the pyrene fluorescence of the WT
N-ABD (10 mM), respectively, upon binding to
F-actin (10 mM). WT protein shows excimer fluo-
rescence, indicating that it is in a closed conforma-
tion when bound to F-actin. For these experiments,
the single-cysteine mutants were labeled by 30%,
whereas the WT protein was labeled such that
the fraction of the doubly labeled protein was 10%.
1976 Singh and Mallelaor the quantum yield of pyrenes increases upon actin
binding because of their inaccessibility to the solvent. Irre-
spective of the reason, the presence of excimer fluorescence
clearly indicates that the dystrophin N-ABD is in a closed
conformation when bound to actin.Comparison of the solution conformation of
dystrophin N-ABD with other tandem CH domains
Our results indicate that dystrophin N-ABD is a monomer in
solution, rather than a domain-swapped dimer observed in
crystallography studies. Similar examples exist in the liter-
ature where soluble monomeric proteins swap their domains
to form oligomers under appropriate solution conditions
(45,46), which implies that observing a domain-swapped
dimer for a protein in its crystal state does not always guar-
antee that the protein is a dimer in solution. For the dystro-
phin N-ABD, dimer formation might have resulted from
solvent conditions used during crystallization, as suspected
earlier (5,26).
Our results on the dystrophin N-ABD, along with that of
utrophin (13,14), fimbrin (15), plectin (16), and a-actinin
(17), indicate that tandem CH domains in general may be
monomeric in solution. In addition, the closed conforma-
tions of the tandem CH domains of dystrophin (shown
here), fimbrin (15), plectin (16), a-actinin (17), and utrophin
(24) indicate that it may be a common conformation forDys N-ABD
CH2
CH1 CH1
CH2
CH1
CH2 CH1
CH2
CH2
CH1
XX
CH1
CH2
Biophysical Journal 103(9) 1970–1978tandem CH domains. However, the actin-bound conforma-
tions may differ between tandem CH domains. We show
here that the dystrophin N-ABD binds to F-actin in a closed
conformation, whereas recent studies indicated that utro-
phin N-ABD binds to F-actin in an open conformation
(24,25). This difference might explain why dystrophin and
utrophin have different modes of binding to actin, and do
not compete with one another for actin binding (11). Similar
solution structural information is needed for other tandem
CH domains to make general conclusions about how they
interact with F-actin.CONCLUSIONS
In summary (Fig. 6), we used the very simple and elegant
technique of pyrene excimer fluorescence to resolve the
three long-standing controversies about the conformation
of the dystrophin N-ABD: 1), it is a monomer in solution;
2), it exists in a closed conformation; and 3) it binds to
F-actin in a closed conformation.
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FIGURE 6 Summary of the results presented in
this study indicate that dystrophin’s tandem CH
domain is a monomer in solution, exists in a closed
conformation, and binds to F-actin in a closed
conformation.
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